Development of Potent, Orally Bioavailable, and Highly Selective LRRK2 PROTAC® Degrader Molecules As Potential Disease Modifying Therapeutics for Parkinson's Disease

K. Kelly,J. Meredith, L. Kimmel, S. Sparks, A. DeSantis, D. Bryce, R. Wilson, J. Corradi, S. Keenan,G. Cadelina,J. Pizzano, A. Cacace

MOVEMENT DISORDERS（2023）

引用 0|浏览9